OX118

About Oxion Biologics

Oxion Biologics is a private, pre-revenue biotech advancing OX118, an Fc-optimized monoclonal antibody targeting OX40L, through clinical development for a broad range of autoimmune conditions. With a first-in-human trial scheduled for Q2 2025 and a granted EU Clinical Trial Application, the company is rapidly progressing towards clinical validation. Its approach aims for true disease modification by selectively depleting pro-inflammatory cells and promoting regulatory T-cell function, targeting a multi-billion dollar market with significant unmet needs.

About Oxion Biologics

Oxion Biologics is a private, pre-revenue biotech advancing OX118, an Fc-optimized monoclonal antibody targeting OX40L, through clinical development for a broad range of autoimmune conditions. With a first-in-human trial scheduled for Q2 2025 and a granted EU Clinical Trial Application, the company is rapidly progressing towards clinical validation. Its approach aims for true disease modification by selectively depleting pro-inflammatory cells and promoting regulatory T-cell function, targeting a multi-billion dollar market with significant unmet needs.

Therapeutic Areas